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940ranges, and differences were analyzed with the Kruskal-Wallis
method. Categorical variables were compared by the chi-square
test or Fisher exact test.
A total of 1,414 PPCI for STE-ACS were performed during
the study period; in 77 patients, TH was used due to a comatose
state after cardiac arrest. The access site for the PPCI was always
femoral in the PPCI-TH group and was radial in 59% of the
PPCI-only group. Baseline characteristics and in-hospital man-
agement are shown in Table 1. All patients received a P2Y12
inhibitor. Clopidogrel was more commonly used in the PPCI-
only group, whereas the PPCI-TH group received signiﬁcantly
more prasugrel. Aspirin was not administered to 33 (2.5%) pa-
tients in the PPCI-only group and 1 (1.3%) patient in the PPCI-
TH group, mainly due to allergy or recent gastrointestinal
bleeding. Both loading and maintenance doses of aspirin in all of
the PPCI-TH–group patients were given intravenously. Glyco-
protein IIb/IIIa inhibitors were more commonly used in the
PPCI-only group.
A mean of 2  1.2 stents were implanted in both groups, with an
overall incidence of ST of 2.3% (n ¼ 32). Among the patients
experiencing ST, 30 (2.3%) were in the PPCI-only group: 17
(1.2%) were acute and 13 (1.0%) were subacute. In the PPCI-TH
group, there were only 2 (2.7%) ST: 1 deﬁnitive acute and 1
probable subacute. Major bleeding, according to GRACE (Global
Registry of Acute Coronary Events) deﬁnition (4), was observed in
6 (8.0%) patients in the PPCI-TH group as compared with 17
(1.3%) in the PPCI-only group (p < 0.001).
All-cause mortality at 30 days of follow-up was signiﬁcantly
higher in the PPCI-TH group than in the PPCI-only group (n¼ 33
[44%] vs. 65 [4.9%], p< 0.001). In the PPCI-THgroup, 31 patients
had a reliable cause of death. Eleven arrived at the hospital in
cardiogenic shock that did not improve despite successful revascu-
larization, and died early due to multiple organ failure (MOF)
without any acute decompensation; 1 died due to liver rupture
related to resuscitation maneuvers; 1 died of unexplained cause
(suspected sepsis), and post-mortem examination revealed absence
of ST; 1 died of brain death; and 17 died due to the withdrawal of
life-sustaining treatment secondary to severe post-anoxic encepha-
lopathy. The other 2 deaths were classiﬁed as ST: 1 deﬁnite acute ST
in a clopidogrel-treated patient complicated with retroperitoneal
bleeding after a new PPCI, and 1 subacute probable ST that died on
the 25th day of evolution due to MOF.
It has been suggested that TH-treated patients may have an
increased risk of ST (2), mainly due to MOF and lower
liver metabolism of drugs that inhibit the ADP P2Y12 receptors
and thromboxane A2 synthesis. In the present observational study,
even under the prelude of greater hemodynamic support and a
higher frequency of hemorrhagic complications in the PPCI-TH–
treated patients, the incidence of ST was almost identical to that of
patients not treated with TH. Therefore, and under the need of
further prospective trials, we believe that adequate antithrombotic
management could be achieved in this population with both the
progressive introduction of third-generation P2Y12 inhibitors and
consideration that the route (intravenous aspirin and crushed
nasogastric P2Y12) (5) and time (before PPCI) of administration
may inﬂuence the ﬁnal result.
In our study, the incidence of ST under the effects of TH is
less than that observed in previous series and similar to that expected
in standard PPCI-treated patients. The described prothrombotic
effects of TH are not clinically relevant in patients treated according
to general recommendations.*Sandra O. Rosillo, MD
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Temporal MicroRNA
ProﬁlesLiebetrau et al. (1) used serial sampling in patients undergoing
transcoronary ablation of septal hypertrophy to determine the
temporal release of microRNAs (miRNAs) after cardiac injury.
This model offers the advantage that the time of onset of myocardial
damage is precisely known. However, heparin is routinely admin-
istered during intra-arterial coronary interventions, including septal
ablation (2). Others (3) and we (4) have recently shown that even a
single heparin bolus is sufﬁcient to signiﬁcantly alter measurements
of miRNA by quantitative polymerase chain reaction, in particular
the spike-in C. elegans control, Cel-miR-39, that was also used for
normalization in the study by Liebetrau et al. (1).
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941In quantitative polymerase chain reaction analysis, the spike-in
control is used to adjust for differences in extraction efﬁciency
between samples (5), and the intersample deviation of Cel-miR-39
measurements is usually less than 1 cycle. However, immediately
after administration of the heparin bolus, the detectability of
Cel-miR-39 decreases by approximately 3 cycles. This effect is
conﬁned to the ﬁrst hours after heparin dosing and directly
related to the half-life of heparin in the circulation. Thus, heparin
could have interfered with the quantitation of miRNA after
transcoronary ablation of septal hypertrophy. The accompanying
editorial noted “the stunning precocity of elevation in the pe-
ripheral circulation of miR-1 and miR-133: only 15 min” (6). If
baseline blood samples were taken before administration of
heparin, then the rapid increase may at least in part be explained
by the effect of heparin on the normalization control. If the
baseline samples were taken after the heparin bolus, then the
reference samples are not suitable for measurements of miRNA
after the ﬁrst hour post-dose. Furthermore, a signiﬁcant increase
in plasma miR-21 levels was previously observed after thigh cuff–
induced ischemia/reperfusion injury (7). Plasma miR-21 levels are
also affected by antiplatelet medication (8). Thus, miR-21 may
not be a suitable control in this setting. Describing the nature
and timing of treatments administered in miRNA biomarker
studies is necessary to facilitate interpretation of data and prevent
confounding by treatment effects.*Manuel Mayr, MD, PhD
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595–600.ReplyEffects of Heparin on
Temporal MicroRNA ProﬁlesWe read with great interest the letter by Dr. Mayr and colleagues
regarding our work and the important topic of the effects of heparin
on temporal microRNA (miRNA) proﬁles and the best timing of
miRNA measurement after administration of heparin. Dr. Mayr
and colleagues were recently able to show that both the timing of
blood sampling relative to heparin dosing and the normalization
procedure are critical for reliable miRNA measurements in patients
receiving intravenous heparin (2,3). At this point, it can clearly be
stated that heparin is not the only confounder in the setting of
miRNA measurements; several factors, including different isolation
protocols, blood sample type (plasma or serum), and inﬂammation-
driven shifts in hematopoietic compartments after myocardial
infarction, appear to further affect the detection of cell-free (truly
circulating) miRNA (4).
With reference to the letter, the baseline blood samples in our
study (1) were taken before administration of heparin. Therefore,
we have a true control for the comparison of miRNA concen-
trations after transcoronary ablation of septal hypertrophy. The
transcoronary ablation of septal hypertrophy procedure itself was
performed after administration of heparin (bolus 5,000 IU hep-
arin). The miRNAs were isolated from serum samples before
miRNA isolation and spiking with native cel-miR-39. The
samples were treated with heparinase to minimize the inﬂuence
of heparin on the miRNA measurements. Of course, we cannot
entirely exclude the further existence of an effect of heparin, but
pre-study tests using the heparinase protocol showed comparable
results for miRNA concentrations with and without heparin.
Furthermore, our results clearly show a steep increase in miR-1
and miR-133a levels (approximately a 30-fold change) within
60 min after induction of myocardial infarction. Even if heparin
were to cause a 30% difference in miRNA concentrations, the
difference compared with miRNA concentrations at 15 min
would still be signiﬁcant.
The patients in our study were without antiplatelet medication.
Therefore, we can exclude the interference of this medication with
the measurement of miR-21 concentrations. Nevertheless, miR-
21 is known to be up-regulated in the presence of cardiac hy-
pertrophy. Thus, an inﬂuence on this subset cannot be entirely
excluded.
Although methodological issues may slightly interfere with the
ﬁnal miRNA measurements, our results add important information
to this new ﬁeld, and miRNAs may well have a future as bio-
markers for myocardial ischemia.*Christoph Liebetrau, MD
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